Log in

XBiotech Stock Price, News & Analysis (NASDAQ:XBIT)

$8.83
+0.06 (+0.68 %)
(As of 10/17/2019 03:58 AM ET)
Today's Range
$8.65
Now: $8.83
$8.97
50-Day Range
$7.92
MA: $9.15
$10.54
52-Week Range
$3.30
Now: $8.83
$11.74
Volume27,079 shs
Average Volume160,103 shs
Market Capitalization$362.13 million
P/E RatioN/A
Dividend YieldN/A
Beta0.44
XBiotech Inc, a pre-market biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The company's lead product is bermekimab, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:XBIT
CUSIPN/A
Phone512-386-2900

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.16 per share

Profitability

Net Income$-21,140,000.00

Miscellaneous

Employees56
Market Cap$362.13 million
Next Earnings Date10/30/2019 (Estimated)
OptionableOptionable

Receive XBIT News and Ratings via Email

Sign-up to receive the latest news and ratings for XBIT and its competitors with MarketBeat's FREE daily newsletter.


XBiotech (NASDAQ:XBIT) Frequently Asked Questions

What is XBiotech's stock symbol?

XBiotech trades on the NASDAQ under the ticker symbol "XBIT."

How were XBiotech's earnings last quarter?

XBiotech Inc (NASDAQ:XBIT) posted its quarterly earnings data on Friday, August, 9th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.15) by $0.01. View XBiotech's Earnings History.

When is XBiotech's next earnings date?

XBiotech is scheduled to release their next quarterly earnings announcement on Wednesday, October 30th 2019. View Earnings Estimates for XBiotech.

What price target have analysts set for XBIT?

1 equities research analysts have issued twelve-month price objectives for XBiotech's stock. Their forecasts range from $13.00 to $13.00. On average, they expect XBiotech's stock price to reach $13.00 in the next year. This suggests a possible upside of 47.2% from the stock's current price. View Analyst Price Targets for XBiotech.

What is the consensus analysts' recommendation for XBiotech?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for XBiotech in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for XBiotech.

Has XBiotech been receiving favorable news coverage?

Media coverage about XBIT stock has trended negative on Thursday, according to InfoTrie. The research firm scores the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. XBiotech earned a media sentiment score of -2.3 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for XBiotech.

Are investors shorting XBiotech?

XBiotech saw a increase in short interest during the month of September. As of September 30th, there was short interest totalling 3,450,000 shares, an increase of 5.2% from the August 30th total of 3,280,000 shares. Based on an average daily volume of 163,100 shares, the short-interest ratio is currently 21.2 days. Approximately 19.2% of the shares of the company are short sold. View XBiotech's Current Options Chain.

Who are some of XBiotech's key competitors?

What other stocks do shareholders of XBiotech own?

Who are XBiotech's key executives?

XBiotech's management team includes the folowing people:
  • Mr. John Simard, Founder, Pres, CEO & Chairman (Age 57)
  • Dr. Sushma Shivaswamy, Chief Scientific Officer (Age 41)
  • Ms. Queena Han B.A., CPA, C.G.A., VP of Fin. & HR and Sec. (Age 52)
  • Mr. Benjamín Guzmán, Sr. VP of Corp. Strategy & Fin. (Age 63)
  • Dr. William Levis, Interim Medical Director and Member of Scientific Advisory Board

When did XBiotech IPO?

(XBIT) raised $76 million in an initial public offering (IPO) on Wednesday, April 15th 2015. The company issued 4,000,000 shares at a price of $18.00-$20.00 per share. WR Hambrecht + Co served as the underwriter for the IPO.

How do I buy shares of XBiotech?

Shares of XBIT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is XBiotech's stock price today?

One share of XBIT stock can currently be purchased for approximately $8.83.

How big of a company is XBiotech?

XBiotech has a market capitalization of $362.13 million. The biopharmaceutical company earns $-21,140,000.00 in net income (profit) each year or ($0.59) on an earnings per share basis. XBiotech employs 56 workers across the globe.View Additional Information About XBiotech.

What is XBiotech's official website?

The official website for XBiotech is http://www.xbiotech.com/.

How can I contact XBiotech?

XBiotech's mailing address is 5217 Winnebago Ln, AUSTIN TX, 78744. The biopharmaceutical company can be reached via phone at 512-386-2900 or via email at [email protected]


MarketBeat Community Rating for XBiotech (NASDAQ XBIT)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  235 (Vote Outperform)
Underperform Votes:  159 (Vote Underperform)
Total Votes:  394
MarketBeat's community ratings are surveys of what our community members think about XBiotech and other stocks. Vote "Outperform" if you believe XBIT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XBIT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/17/2019 by MarketBeat.com Staff

Featured Article: Stocks Increasing Dividends

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel